Abstract: Methods for identifying cancer patients amenable to anti-cancer immunotherapy are provided along with methods of monitoring cancer therapy. Also provided are methods of treating cancer patients amenable to anti-cancer immunotherapy. The methods involve determining the level of CD127 <low> PD-1 <low> T cells. The patients are treated with an immune checkpoint inhibitor, such as an anti-CTLA-4 antibody, e.g. ipilimumab.

Abstract: The present disclosure relates generally to, inter alia, therapeutic and diagnostic methods and compositions for treatment of bladder cancer. In particular, the disclosure relates to defining pre-treatment gene signatures that are predictive of response to anti-PD-L1 therapy and to the use of such gene signatures as biomarkers to identify individuals having or suspected of having bladder cancer who are most likely to respond to an anti-PD-L1 therapy. In some embodiments, various methods for the treatment of bladder cancer in individuals identified by the diagnostic methods disclosed herein are also provided.

Abstract: The disclosure provides methods of determining patient populations amenable or suitable for immunomodulatory treatment of disease such as cancer by measuring the relative or absolute levels of T-cell sub-populations correlated with disease such as cancer.

Abstract: Provided herein, inter alia, are compositions and methods for treating bladder cancer, including CD4+T cells that can be cultured ex vivo to generate a population of cytotoxic CD4+T cells capable of killing bladder cancer tumor cells. Pharmaceutical compositions containing such a cytotoxic CD4+T cell population, as well as methods for treating an individual having or suspected of having bladder cancer are also provided.

Abstract: The disclosure provides methods of determining patient populations amenable or suitable for immunomodulatory treatment of disease such as cancer by measuring the relative or absolute levels of T-cell sub-populations correlated with disease such as cancer.

Abstract: T-cells that does not express a functional Interferon-? (IFN-?) receptor are provided as well as methods of treating cancers with the T-cells, optionally in combination with immune checkpoint pathway inhibitors.

Abstract: Methods for identifying cancer patients amenable to anti-cancer immunotherapy are provided along with methods of monitoring cancer therapy. Also provided are methods of treating cancer patients amenable to anti-cancer immunotherapy. The methods involve determining the level of CD127<low>PD-1<low>T cells. The patients are treated with an immune checkpoint inhibitor, such as an anti-CTLA-4 antibody, e.g. ipilimumab.

Abstract: The disclosure provides methods of determining patient populations amenable or suitable for immunomodulatory treatment of disease such as cancer by measuring the relative or absolute levels of T-cell sub-populations correlated with disease such as cancer.

Abstract: The disclosure provides methods of improving the effectiveness of an immunomodulatory cancer therapy by selecting a patient population amenable to immunomodulatory cancer therapy and methods of selecting cancer patient populations amenable to immunomodulatory therapy by measuring T cell repertoire clonality as well as methods of selecting cancer patients at reduced risk of developing an adverse event in response to such therapy. Also provided are methods of screening for adjuvants for immunomodulatory cancer therapy by measuring the frequency or severity of at least one adverse event that develops in response to the therapy.

Abstract: The invention is directed to a method of predicting clinical response of a patient to treatment of a cancer by an immune checkpoint pathway inhibitor, such as an anti-CTLA-4 or anti-PD-1 antibody binding compound. In one aspect the method comprises generating pre- and post-treatment clonotype profiles, determining a number of clonotypes that decrease in frequency between the first and second clonotype profiles, and predicting a lack of responsiveness in the patient to the treatment whenever the number of clonotypes that decrease in frequency is greater than a predetermined value.